Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).

7 Jun 2011

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Biogen Idec today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like symptoms associated with the therapy.

6 Jun 2011

New approach for identifying 'self' proteins targeted in autoimmune diseases

Researchers from Harvard Medical School and MIT have developed a new approach for identifying the "self" proteins targeted in autoimmune diseases such as multiple sclerosis, diabetes and rheumatoid arthritis.

3 Jun 2011

Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis

Teva Pharmaceutical Industries Ltd. today announced completion of patient enrollment for the GALA (Glatiramer Acetate Low-frequency Administration) trial.

3 Jun 2011

RegeneRx Thymosin beta 4 stimulates maturation of central nervous system progenitor cells

RegeneRx Biopharmaceuticals, Inc. has announced that researchers have found that Thymosin beta 4 (Tβ4), in a dose dependent manner, stimulates oligodendrogenesis, the process by which central nervous system progenitor cells become oligodendrocytes that secrete myelin, the covering of nerve fibers.

2 Jun 2011

Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application to market a generic version of Eisai's Alzheimer's treatment Aricept Tablets, 5 mg and 10 mg. Shipment of this product has commenced.

2 Jun 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients — estimated to be as many as 1 million in the U.S. — drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

1 Jun 2011

Increased stress not linked to multiple sclerosis

According to a new study that refutes earlier evidence, stress does not appear to increase a person's risk of developing multiple sclerosis (MS). The research is published in the May 31, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

31 May 2011

Stress does not appear to increase risk of developing multiple sclerosis

Contrary to earlier reports, a new study finds that stress does not appear to increase a person's risk of developing multiple sclerosis. The research is published in the May 31, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

31 May 2011

Improvements to Medicare prescription drug program benefit MS patients in the 'donut hole'

As the average cost of MS in the United States is nearly $70,000 a year, with the overall annual economic cost of MS being an estimated $28 billion, people living with MS face high out-of-pocket costs even when covered by health insurance.

30 May 2011

ENS, SSIF announce prestigious award to recognize excellence in medical education

Serono Symposia International Foundation (SSIF) has announced today a public competition for an Award to recognise an expert in the field of neurology who has made a significant contribution to medical education activities through research and dedication.

30 May 2011

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

UCB today announced data which showed that the addition of Cimzia to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.

30 May 2011

Vitamin D levels low in African Americans with multiple sclerosis

In the first major study exploring the connection between vitamin D and multiple sclerosis in African Americans, a team of scientists at the University of California, San Francisco has discovered that vitamin D levels in the blood are lower in African Americans who have the disease, compared to African Americans who do not.

30 May 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

27 May 2011

Nuron secures option, license deal to develop NU400 for Relapse Remitting Multiple Sclerosis

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has secured an exclusive option and license agreement utilizing PolyTherics' site-specific TheraPEG PEGylation technology to develop NU400, a long-acting version of Nuron's proprietary recombinant human interferon beta-1b.

27 May 2011

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients - estimated to be as many as 1 million in the U.S. - drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

26 May 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Proteostasis Therapeutics and Elan Corporation today announced a strategic business relationship to advance Proteostasis' platform for the discovery and development of disease-modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders such as Parkinson's, Huntington's, multiple sclerosis and amyotrophic lateral sclerosis, and a broad array of dementia-related diseases including Alzheimer's.

25 May 2011

Biogen Idec launches educational forum, 'Women in MS'

Biogen Idec today announced the launch of "Women in MS," an educational initiative to address both the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis.

25 May 2011

BPD expands existing bioprocess and scale-up laboratory in Poway, CA

Biologics Process Development Inc., a wholly-owned subsidiary of Viropro, will double the size of its existing bioprocess- and scale-up laboratory in Poway, CA.

25 May 2011

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

New approach for identifying 'self' proteins targeted in autoimmune diseases

Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis

RegeneRx Thymosin beta 4 stimulates maturation of central nervous system progenitor cells

Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Increased stress not linked to multiple sclerosis

Stress does not appear to increase risk of developing multiple sclerosis

Improvements to Medicare prescription drug program benefit MS patients in the 'donut hole'

ENS, SSIF announce prestigious award to recognize excellence in medical education

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

Vitamin D levels low in African Americans with multiple sclerosis

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

Nuron secures option, license deal to develop NU400 for Relapse Remitting Multiple Sclerosis

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Biogen Idec launches educational forum, 'Women in MS'

BPD expands existing bioprocess and scale-up laboratory in Poway, CA

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in